Novavax, Inc. (NASDAQ: NVAX) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Novavax, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.96, Novavax, Inc. trades at 3.2x sales. Over the last twelve months it generated about $411M of revenue and a net loss of $76M. It runs a gross margin of 77.3%, an operating margin of -19.6% and a net margin of -18.6%. It shows return on equity of 45.1%, return on invested capital of -14.4% and a free cash flow yield of -18.8%. On the balance sheet: a debt-to-equity ratio of -1.36 and a current ratio of 2.15. Over the past 52 weeks the share price ranged from $6.20 to $13.39, with a beta of 2.72.
Novavax, Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 16 Buy, 3 Hold and 4 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.